Abstract
Objectives: Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that slows gastrointestinal (GI) motility. Whether exenatide produces clinically detectable GI motility slowing in real-world practice — and how this compares to other GLP-1 RAs — has not been systematically evaluated. We addressed this question using federated, electronic health record (EHR) data. Further, we present clinical data on vurolenatide, a long-acting variant of exenatide, in patients with short bowel syndrome (SBS), a condition defined by nutritional insufficiency where reducing GI motility could be beneficial to patient outcomes. Methods: We queried de-identified EHR data on the nSights platform to identify treatment episodes for exenatide, semaglutide, and tirzepatide among patients with documented GI hypermotility. Anti-constipation medication prescriptions, body weight, and HbA1c trajectories were compared between pre- and post-treatment periods. Given exenatide’s GI potency, we enrolled 9 SBS patients in a Ph 1b/2a study looking at vurolenatide, dosed subcutaneously every 2 weeks. Safety, tolerability, total urine output, and total stool output were the primary endpoints with the latter serving as a metric for GI motility. Results: We identified patients on exenatide (n=387), semaglutide (10,315), and tirzepatide (5,095) and found the prevalence of anti-constipation prescriptions increased significantly in the exenatide cohort over 12 months (11.09% to 18.62%; p=6.75×10⁻⁴). No significant change was detected with semaglutide (17.54% to 17.70%, p=0.734), and tirzepatide was associated with a decrease in use (18.72% to 14.84%, p<0.001). Exenatide did not impact body weight (-0.5%, p=0.299), compared to semaglutide (-3.95%, p<0.001) and tirzepatide (-8.44%, p<0.001), nor impact HbA1c (-0.02 %-points, p=0.926), compared to semaglutide (-0.26 %-points, p<0.001) and tirzepatide (-0.56 %-points, p<0.001). Consistent with exenatide’s potency at slowing GI motility, biweekly dosing of vurolenatide in human SBS patients showed immediate reduction in total stool output and in the number of bowel movements patients experienced. Conclusions: Exenatide is associated with potent slowing of GI motility in retrospective analysis of EHR data as well as in prospective treatment of SBS patients. This real-world signal proxies the mechanism underlying vurolenatide in SBS and provides a first-in-kind pharmacoepidemiological basis for GLP-1 RA–mediated modulation of GI motility.

This publication has 18 references indexed in Scilit: